Mucosal IgA fused nanobody as a non-invasive, cost-effective

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

Related Keywords

United States , , Coronavirus Disease Covid 19 , Prophylaxis , Cars , Ars Cov 2 , Antibodies , Ntibody , Coronavirus , Covid 19 , Efficacy , Mmunoglobulin , Mmunology , N Vivo , Manufacturing , Monoclonal Antibody , Ortality , Nanobodies , Micron , Pandemic , Protein , Eceptor , Espiratory , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Spike Protein , Yndrome , Ransgenic , Least ,